Disclosed are pyrazole derivatives of formula (I), wherein the variables are as defined in the specification, which are calcium release-activated calcium (CRAC) channel inhibitors methods for preparing them pharmaceutical compositions containing them and methods of treatment using them. These compounds are suitable for treating non-small cell lung cancer (NSCLC), and for identifying therapeutics for treating and of diagnosing cancer, and are also suitable for the treating autoimmune disorder and inflammation.
